Related Experiment Videos
A slow release formulation for recombinant bovine interferon alpha I-1
H P Hughes1, S Rossow, M Campos
1Veterinary Infectious Disease Organization, Saskatoon, Canada.
Antiviral Research
|January 1, 1994
Summary
A new slow-release formulation of recombinant bovine interferon-alpha I1 (rBoIFN-alpha) effectively sustained therapeutic levels for 8 days. This extended protection offers a promising strategy for preventing bovine respiratory disease in cattle.
Area of Science:
- Veterinary Immunology
- Pharmacokinetics
- Biologics Formulation
Background:
- Recombinant bovine interferon-alpha I1 (rBoIFN-alpha) exhibits antiviral and immunomodulatory properties beneficial for managing bovine respiratory diseases.
- Current prophylactic strategies may be limited by the short duration of action of existing rBoIFN-alpha formulations.
- Developing a sustained-release formulation could enhance the efficacy of rBoIFN-alpha in preventing bovine respiratory disease under field conditions.
Purpose of the Study:
- To develop and characterize a novel slow-release formulation of rBoIFN-alpha.
- To evaluate the pharmacokinetic profile and biological activity of the sustained-release formulation in cattle.
- To assess the potential of this formulation for improving the prevention of bovine respiratory disease.
Main Methods:
- A formulation of rBoIFN-alpha in sesame oil with calcium stearate was developed for slow release.
- Serum concentrations of rBoIFN-alpha were measured over 8 days post-injection.
- Immunological parameters including lymphocyte populations (CD4, CD8, gamma delta T cells), neutropenia, and 2-5 oligoadenylate (2-5 A) synthetase activity were assessed.
Main Results:
- The formulation demonstrated sustained release of rBoIFN-alpha over an 8-day period, with an initial release burst at 6 hours post-injection.
- Serum levels reached 12-15 ng/ml and 25 ng/ml for 50 mg and 100 mg doses, respectively.
- While transient changes in CD4-CD8- gamma delta+ T lymphocytes and slight neutropenia were observed, 2-5 A synthetase levels remained elevated for 8 days, indicating prolonged antiviral potential.
Conclusions:
- The developed slow-release rBoIFN-alpha formulation successfully provides sustained drug levels and biological activity for 8 days.
- The prolonged elevation of 2-5 A synthetase suggests enhanced and extended antiviral protection compared to conventional formulations.
- This sustained-release approach holds promise for improving the prophylactic efficacy of rBoIFN-alpha against bovine respiratory disease.